Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a ‘high,’ was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox-Gastaut syndrome. This study also is the first to offer information on cannabidiol dosing for patients with treatment-resistant epilepsy.